TolerogenixX GmbH
Christian Morath began their work experience in 2002 as the Deputy Medical Director at Nierenzentrum. In 2016, they transitioned to the role of Chief Scientific Officer at TolerogenixX GmbH, where they currently serve.
Christian Morath attended Heidelberg University from 1994 to 2001, where they obtained a Dr. med. degree in Medizin. Later, from 2013 to 2017, they pursued a Master's degree in Health and Business Administration at FAU Erlangen-Nürnberg.
This person is not in any teams
TolerogenixX GmbH
High-Tech Gründerfonds (HTGF) is Germany’s most active seed stage investor. With EUR 576 million under management in two funds we provide financing for technology-driven companies active in a wide range of fields, including robotics, IoT and energy, Medtech and Biotech, chemicals and software. Investors in this public-private partnership includethe German Federal Ministry of Economics and Energy, the KfW Banking Group, and 18 strategic corporate investors.